CSL Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMXHF research report →
Companywww.csl.com.au
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
- CEO
- Gordon Naylor DipCompSc
- IPO
- 2005
- Employees
- 32,698
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $34.29B
- P/E
- 23.85
- P/S
- 2.17
- P/B
- 1.84
- EV/EBITDA
- 8.83
- Div Yield
- 4.27%
Profitability
- Gross Margin
- 48.64%
- Op Margin
- 25.72%
- Net Margin
- 9.17%
- ROE
- 7.56%
- ROIC
- 10.37%
Growth & Income
- Revenue
- $15.43B · 4.26%
- Net Income
- $3.00B · 13.63%
- EPS
- $6.20 · 13.35%
- Op Income
- $2.96B
- FCF YoY
- 68.92%
Performance & Tape
- 52W High
- $184.09
- 52W Low
- $67.74
- 50D MA
- $91.30
- 200D MA
- $117.23
- Beta
- 0.14
- Avg Volume
- 3.75K
Get TickerSpark's AI analysis on CMXHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CMXHF Coverage
We haven't published any research on CMXHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMXHF Report →